<SEC-DOCUMENT>0001213900-17-007981.txt : 20170727
<SEC-HEADER>0001213900-17-007981.hdr.sgml : 20170727
<ACCEPTANCE-DATETIME>20170727171000
ACCESSION NUMBER:		0001213900-17-007981
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20170727
DATE AS OF CHANGE:		20170727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-207635
		FILM NUMBER:		17987033

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>f424b5072717_immucellcorp.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed Pursuant
to Rule 424(b)(5)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No.: 333-207635</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>PROSPECTUS
SUPPLEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
Prospectus dated November 10, 2015)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>200,000
Shares of Common Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>ImmuCell
Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering 200,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common
stock is listed on The Nasdaq Capital Market under the symbol &ldquo;ICCC&rdquo;. On July 25, 2017, the last reported sale price
of our common stock on The Nasdaq Capital Market was $6.72 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves certain risks. Before deciding whether to invest in our securities, you should review carefully the
information described under the heading &ldquo;Risk Factors&rdquo; beginning on page S-8 of this prospectus supplement, on page
5 of the accompanying prospectus, in our Annual Report on Form 10-K for the year ended December 31, 2016, and in our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2017.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,050,000.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds, after expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,026,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 25, 2017, the aggregate market value of our outstanding common equity held by non-affiliates was approximately $26,751,000
based on 4,848,390 shares of outstanding common stock, of which 867,592 shares are held by affiliates, and a price of $6.72 per
share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on July 25, 2017. As of the date
of this prospectus supplement, we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3 during the prior
12-calendar month period that ends on, and includes, the date of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary
is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
date of this prospectus supplement is July 27, 2017.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; width: 89%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0; text-indent: 0; width: 10%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About This Prospectus Supplement</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Supplement Summary</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary Financial Data</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price Range of Our Common Stock</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-12</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-13</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Documents by Reference</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-15</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; width: 89%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0; text-indent: 0; width: 10%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp1">Cautionary Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp2">About this Prospectus</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp3">About ImmuCell Corporation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp4">Where You Can Find Additional Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp5">Incorporation of Information by Reference</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp6">Risk Factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp7">Description of Securities We May Offer</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp8">Description of Common Stock</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp9">Description of Warrants</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp10">Description of Units</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp11">Use of Proceeds</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp12">Plan of Distribution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp13">Legal Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp14">Experts</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#bp15">Interests of Named Experts and Counsel</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the Securities and
Exchange Commission, or the SEC, utilizing a &ldquo;shelf&rdquo; registration process. Under this process, we may sell from time
to time in one or more offerings up to an aggregate of $10,000,000 of our securities described in the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and
also adds to and updates information contained in the accompanying prospectus. The second part is the accompanying prospectus,
which provides general information, some of which may not apply to this offering. If information in this prospectus supplement
is inconsistent with the accompanying prospectus, you should rely on this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in or incorporated by reference in this prospectus supplement and the accompanying
prospectus. We have not authorized any other person to provide you with different information. If anyone provides you with different
or inconsistent information, you should not rely on it. We are making an offer to sell common stock only in jurisdictions where
offers and sales are permitted. You should assume that the information appearing in this prospectus supplement, in the accompanying
prospectus and in the documents incorporated by reference is accurate only as of their respective dates or other dates which are
specified in those documents. Our business, financial condition, results of operations and prospects may have changed since those
dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is important for you to read and consider all of the information contained in or incorporated by reference in this prospectus
supplement and the accompanying prospectus in making your investment decision. See &ldquo;Where You Can Find More Information&rdquo;
on page S-15 of this prospectus supplement and &ldquo;Where You Can Find Additional Information&rdquo; on page 3 of the accompanying
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, references in this prospectus supplement to &ldquo;ImmuCell&rdquo;, the &ldquo;Company&rdquo;,
&ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo;, or similar terms, refer to ImmuCell Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_002"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the statements contained in or incorporated by reference in this prospectus supplement and in the accompanying prospectus that
are not historical facts constitute &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events concerning our business
and to our future revenues, operating results and financial condition, and involve a number of known and unknown risks, uncertainties
and other factors that could cause our actual results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as &ldquo;may&rdquo;, &ldquo;will&rdquo;, &ldquo;could&rdquo;, &ldquo;would&rdquo;,
&ldquo;should&rdquo;, &ldquo;expect&rdquo;, &ldquo;plan&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;aim&rdquo;, &ldquo;intend&rdquo;,
&ldquo;believe&rdquo;, &ldquo;estimate&rdquo;, &ldquo;target&rdquo;, &ldquo;forecast&rdquo;, &ldquo;predict&rdquo;, &ldquo;project&rdquo;,
&ldquo;propose&rdquo;, &ldquo;potential&rdquo;, or &ldquo;continue&rdquo;, or the negative of those terms or other comparable
terminology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
statements are only estimates or predictions of future events based on information currently available to our management and management&rsquo;s
current beliefs about the potential outcome of future events. There are a number of important factors that could cause actual
results to differ materially from the results anticipated by these forward-looking statements, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our reliance on sales of our existing products;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our dependence on a small number of significant customers
and the concentration of our existing product sales;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to complete the development of (including
obtaining required regulatory approvals for), and to achieve successful commercialization of, a key new product;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk of cost overruns or delays in constructing
our expanded manufacturing facility, including inadequacy of available funding for the project;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainties arising from the volatile economics of
the dairy and beef cattle industries;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks related to ongoing regulatory compliance and associated
substantial costs;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our dependence on third parties for raw materials and
manufacturing services;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitive pressures from larger and better capitalized
competitors;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Possible technical obsolescence or loss of cost competitiveness
of our products;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our small size and dependence on key personnel;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks of product recalls and product liability claims;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks of sales order backlogs and possible loss of key
customers due to product delivery issues or concerns;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated with incurring substantial additional
indebtedness and utilizing a substantial portion of our working capital to fund our facilities expansion and new product commercialization
efforts;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our reliance on our intellectual property rights and
risks associated with protecting such rights; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other risks listed in Item 1A. &ldquo;Risk Factors&rdquo;
of our Annual Report on Form 10-K for the year ended December 31, 2016, or in Item 1A. &ldquo;Risk Factors&rdquo; of our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2017, which are incorporated by reference in this prospectus supplement and
the accompanying prospectus.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual
results. Forward-looking statements contained in or incorporated by reference in this prospectus supplement and the accompanying
prospectus present our views only as of the date of the applicable document containing such forward-looking statements. We do
not assume any obligation, and do not intend, to update any forward-looking statement except as required by law. All forward-looking
statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5; padding-left: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_003"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights information contained in or incorporated by reference in this prospectus supplement. It does not contain all
the information you should consider before investing in shares of our common stock. Before deciding to invest in shares of our
common stock, you should carefully read this entire prospectus supplement, the accompanying prospectus and the documents incorporated
herein and therein by reference, including the &ldquo;Risk Factors&rdquo; beginning on page S-9 of this prospectus supplement,
our financial statements and the related notes and other information that is incorporated by reference in this prospectus supplement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ImmuCell
Corporation is a rapidly growing animal health company focused on developing, manufacturing and delivering scientifically-proven,
practical and effective products that result in measurable positive economic impacts on animal health and productivity in the
dairy and beef industries. Our lead product, <B>First Defense</B><SUP>&reg;</SUP>, is derived from colostrum collected from dairy
cows and provides significant, immediate immunity against scours in newborn dairy and beef cattle. We are in the late stages of
developing and securing final regulatory approvals for an intramammary treatment for subclinical mastitis in lactating dairy cows,
the active ingredient of which is Nisin, an antibacterial peptide that has been demonstrated in clinical studies to be an effective
aid in the reduction of mastitis-causing organisms in dairy cows. We currently expect to be in a position to commence commercial
sales of our new product in the United States in the second half of 2019 (subject to receipt of final approvals from the U.S.
Food and Drug Administration&rsquo;s Center for Veterinary Medicine (FDA)). Across all product lines, our product sales during
the twelve month period ended March 31, 2017 decreased by 0.1%, or $12,025, to $10,101,532 from $10,113,557 for the twelve months
ended March 31, 2016, and gross margin as a percentage of product sales was 57.6% during the twelve months ended March 31, 2017,
as compared to 60.9% during the twelve months ended March 31, 2016<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of <B>First Defense</B><SUP>&reg;</SUP> and related product line extensions aggregated 92.8% and 91.6% of our total product sales
during the twelve months ended March 31, 2017 and the twelve months ended March 31, 2016, respectively. Sales of <B>First Defense</B><SUP>&reg;
</SUP>and related product line extensions increased by 1.2% and 14.4% during the twelve months ended March 31, 2017 and March
31, 2016, respectively, in comparison to the corresponding prior full twelve month periods. We estimate that sales of <B>First
Defense</B><SUP>&reg;</SUP> and related product line extensions decreased by 9% during the twelve months ended June 30, 2017,
as compared to the twelve months ended June 30, 2016. <B>First Defense</B><SUP>&reg;</SUP> is manufactured from hyper-immune cows&rsquo;
colostrum (the milk that a cow produces immediately after giving birth) utilizing our proprietary vaccine and milk protein purification
technologies. The target disease, bovine enteritis (calf scours), causes diarrhea and dehydration in newborn calves and often
leads to serious sickness and even death. <B>First Defense</B><SUP>&reg;</SUP> is the only orally delivered scours preventive
product on the market for calves that is licensed by the U.S. Department of Agriculture (USDA) with claims against <I>E. coli
</I>K99 and coronavirus (two leading causes of scours). We are actively pursuing licensing of <B>First Defense</B><SUP>&reg;</SUP>
for claims against rotavirus, which could further favorably differentiate our product from the competition. <B>First Defense</B><SUP>&reg;
</SUP>provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Our
milk antibody products provide <B>Immediate Immunity</B>&trade; during the first few critical days of life when calves need this
protection most. Studies have shown that calves that scour are more susceptible to other diseases later in life and under-perform
calves that do not contract scours. We estimate that scours causes approximately $740 million in economic losses to the U.S. dairy
and beef industries per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5; padding-left: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Novel
Treatment for Subclinical Mastitis in Lactating Dairy Cows (under development)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
majority of our product development budget since 2000 has been focused on the development of a Nisin-based intramammary
treatment of subclinical mastitis in lactating dairy cows. Mastitis is a very common infection in dairy cows that results in
inflammation of the mammary gland. It is the largest single cause of economic harm to the U.S. dairy industry, with an
estimated cost of approximately $2 billion per year, including approximately $300 million in discarded milk from cows that
have been treated with traditional antibiotic mastitis drugs. During the period that began on January 1, 2000 (the year we
began the development of our product) and ended on March 31, 2017, we invested an aggregate of approximately $12,624,000 in
the development of this product. This estimated allocation of product development expenses reflects only direct expenditures
and includes no allocation of product development or administrative overhead expenses. Approximately $2,891,000 of this
investment was offset by related product licensing revenues and grant income. Nisin is an antibacterial peptide that has been
demonstrated in clinical studies to be an effective aid in the reduction of mastitis-causing organisms in dairy cows. Because
dairy producers are required to discard milk for a period during and after treatment with all currently marketed mastitis
treatment products due to concerns about antibiotic residue in milk, it is generally current practice to only treat mastitis
when the disease has progressed to the clinical stage where the milk from an infected cow cannot be sold. We believe that our
product could revolutionize the way that mastitis is treated in the United States by making earlier treatment of
subclinically infected cows economically feasible by not requiring a milk discard during, or for a period of time after,
treatment. No other FDA-approved mastitis treatment product on the market can offer this value proposition. Growing concerns
about the presence of traditional antibiotics in our food supply, we believe, will aid in the marketing of our product and
growth in its sales. Based on publicly available information on the size of the U.S. dairy herd, the incidence of mastitis
and likely mastitis treatment protocols, we have estimated first year commercial sales of our product could be $5.8 million
with potential growth for the fifth year to $36.1&nbsp;million. Commercial introduction of our product in the United
States is subject to approval of our New Animal Drug Application by the FDA, which approval cannot be assured. Foreign
regulatory approvals would be required for sales in key markets outside of the United States, which would involve some
similar and some different requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Facilities Expansion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
presently operate a facility that produces Nisin, the active ingredient in our novel mastitis treatment, only in small quantities,
which has been adequate for purposes of product testing and evaluation and process yield optimization. We had previously entered
into an agreement with a multi-national pharmaceutical ingredient manufacturer for our commercial-scale supplies of Nisin. However,
we determined in 2014 that that agreement did not offer us the most advantageous supply arrangement in terms of either cost or
long-term dependability. As a result, we undertook design work on construction of a new manufacturing facility that would enable
us to generate our own Nisin supply at commercial scale, with sufficient capacity to meet approximately 35% of the estimated sales
potential for the product by the fifth year of sales. Our facility is being constructed with enough room for a second production
line to be purchased and installed to effectively double production output. We would evaluate all Nisin supply options, but building
an additional Nisin production facility to meet our needs could be the most cost-effective solution if sales exceed approximately
70% of the estimated sales potential for this product by the fifth year of sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the third quarter of 2016, we commenced construction of our Nisin production facility adjacent to our existing facilities in Portland,
Maine. The estimated total cost of the Nisin facility is $20.2 million. We are substantially complete with construction of the
building shell and have made significant progress on the interior of the building. As anticipated we began equipment installation
during the third quarter of 2017. We expect equipment installation and qualification to be complete by year end. We anticipate
making the first submission of the manufacturing Technical Section to the FDA during 2018. We anticipate that two submissions
will be required. Each submission is subject to a six-month review by the FDA. After approval of this final Technical Section,
there is a 60-day administrative review before product license approval could be issued. Adherence to this anticipated timeline
sets us up for an expected market launch during the second half of 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to fund the remaining costs of this investment (estimated to be $10,034,000 as of June 30, 2017) that are in excess of
our estimated cash and investments of $4,337,000 as of June 30, 2017 with borrowings under our $6,000,000 of available credit
facilities with TD Bank N.A. These credit facilities were originally entered into in 2016 in anticipation of the need to construct
such a facility and totaled $4.5 million. These facilities were amended in the first quarter of 2017 to increase to $6.5 million,
in addition to a separate $500,000 line of credit, in light of increases in the expected total cost of constructing and equipping
the facility. As of June 30, 2017, we had drawn $500,000 on the equipment loan and $500,000 on the line of credit. We believe
that cash flows from our current commercial sales will be sufficient to service our debt and maintain compliance with our bank
debt covenants until sales of our new product are initiated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5; padding-left: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Historical and ProForma Balance Sheet Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents unaudited summary balance sheet data as of March 31, 2017 on both a historical basis and on an as adjusted
basis (assuming that the credit facilities described above had been fully drawn, the estimated project spend on the Nisin facility
of $20,163,000 had occurred, and the proceeds of this offering had been received, as of March 31, 2017). The summary financial
data has been derived from our unaudited financial statements, which are incorporated by reference in this prospectus supplement.
The as adjusted summary financial data is not necessarily indicative of what our financial position or results of operations would
have been if this offering had been completed as of the date indicated, nor is such data necessarily indicative of our financial
position for any future date. The following summary and as adjusted financial data should be read in conjunction with, and are
qualified in their entirety by reference to, &ldquo;Use of Proceeds&rdquo;, &ldquo;Capitalization&rdquo;, &ldquo;Summary Financial
Data&rdquo;, and our financial statements and the related notes included elsewhere in this prospectus supplement or incorporated
by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR>
 March 31,<BR>
 2017<BR> (Actual)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> March 31,<BR>
 2017<BR> (As Adjusted)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.125in">Total current assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">10,911,869</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,242,895</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Property, plant and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,124,778</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,972,378</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Intangible Assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167,160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167,160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,557</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Other assets, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">34,264</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">34,264</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total Assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">25,333,628</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">32,512,254</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Liabilities and Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,762,348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,414,974</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Total long-term liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">3,202,812</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">9,702,812</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,965,160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,117,786</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total Stockholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">20,368,468</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">21,394,468</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">25,333,628</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">32,512,254</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a growing animal health company whose purpose is to create scientifically-proven and practical products that result in a measurable
economic impact on animal health and productivity in the dairy and beef industries. We were originally incorporated in Maine in
1982 and reincorporated in Delaware in 1987, in conjunction with our initial public offering of common stock. Our principal executive
offices are located at 56 Evergreen Drive, Portland, Maine 04103. Our telephone number is (207) 878-2770. We maintain an Internet
website at <I>www.immucell.com</I>. The information contained in, or accessible from, our website is not a part of this prospectus
supplement or the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5; padding-left: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary contains basic information about this offering. The summary is not intended to be complete. You should read
the full text and more specific details contained elsewhere in this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 25%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock offered by us</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 74%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000
    shares of common stock, par value $0.10 per share. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock outstanding immediately after this offering<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,048,390
    shares of common stock. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of proceeds</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    estimate that our net proceeds from this offering will be approximately $1,026,000, after deducting our estimated expenses
    related to the offering. We intend to use the net proceeds from this offering of common stock, to provide additional working
    capital. See &ldquo;Use of Proceeds.&rdquo; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    Factors</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    the information described under the heading &ldquo;Risk Factors&rdquo; beginning on page S-9 of this prospectus supplement
    and other information contained in or incorporated by reference in this prospectus supplement and the accompanying prospectus
    for a discussion of factors you should consider carefully before investing in our common stock.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
    Capital Market symbol</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ICCC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares of common stock that will be outstanding
immediately after this offering is based on 4,848,390 shares outstanding as of March 31, 2017, and excludes 368,000 shares of
our common stock reserved for future issuance upon the exercise of outstanding options (of which options with respect to 162,000
shares are currently exercisable). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5; padding-left: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_004"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUMMARY
FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following table sets forth, for the periods and dates indicated, our summary financial data. The summary financial data has been
derived from our unaudited historical consolidated financial statements and accompanying notes for the three months ended March
31, 2017 and the three months ended March 31, 2016. The results included in this table are not necessarily indicative of future
performance. The following table should be read in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; and the audited historical financial statements and accompanying notes thereto included
in our Annual Report on Form 10-K for the year ended December 31, 2016 and the unaudited historical financial statements and accompanying
notes thereto included in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, which are incorporated by reference
in this prospectus supplement and the accompanying prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>(In thousands, except per share amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2017 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2016 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.125in">Product sales</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,544</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,986</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Cost of goods sold</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,392</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,228</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Gross margin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,758</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Selling and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">757</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Product development expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">340</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">302</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Operating Expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,234</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Net operating income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">918</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">699</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Other expenses, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Income before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">675</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Income tax expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">304</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">223</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Net income</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">584</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">452</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average common shares outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,848</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,833</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,940</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,944</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Net income per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the process of finalizing our results for the six-month period and quarter ended June 30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on currently available information, we estimate that, as of and for the six-month period and the second quarter ended June 30,
2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
sales during the six-month period ended June 30, 2017 are anticipated to be approximately $5,294,000 compared to $5,362,000 during
the six-month period ended June 30, 2016, a decrease of $68,000 or 1%;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
sales for the second quarter of 2017 are anticipated to be approximately $1,750,000 compared to $2,376,000 in the prior year&rsquo;s
second quarter, a decrease of $626,000 or 26%; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
cash equivalents and short-term investments are anticipated to be approximately $4,337,000 as of June 30, 2017, as compared to
$10,624,000 as of December 31, 2016.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
unaudited preliminary financial information for the six-month period and quarter ended June 30, 2017 is based upon our estimates
and subject to completion of our financial closing procedures. Moreover, these data have been prepared solely on the basis of
currently available information by, and are the responsibility of, management. This preliminary financial information is not a
comprehensive statement of our financial results for this period, and our actual results may differ materially from these estimates
due to the completion of our financial closing procedures, final adjustments, and other developments that may arise between now
and the time the closing procedures for the quarter are completed. There can be no assurance that these estimates will be realized,
and estimates are subject to risks and uncertainties, many of which are not within our control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_005"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our securities involves risk. You should consider carefully the risk factors described below and set forth in the
&ldquo;Risk Factors&rdquo; sections of the Annual Report on Form 10-K for the year ended December 31, 2016 and the Quarterly Report
on Form 10-Q for the quarter ended March 31, 2017, together with the other information contained in our financial statements and
the related notes, which are incorporated by reference herein, before deciding to invest in our common stock. We operate in a
changing environment that involves numerous known and unknown risks and uncertainties that could materially adversely affect our
operations. If any of such risks materialize, our business, financial condition, results of operations and the value of our common
stock could be materially and adversely affected. In such case, you may lose all or part of your investment in our common stock.
Please also refer to the section above entitled &ldquo;Forward-Looking Statements&rdquo; regarding forward-looking statements
included or incorporated herein by reference.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to This Offering and Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
will experience immediate dilution in the book value per share of the common stock you purchase.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our
common stock, you will suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering.
If you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of approximately $1.06
per share in the net tangible book value of the common stock. See the section entitled &ldquo;Dilution&rdquo; below for a more
detailed discussion of the dilution you will incur if you purchase common stock in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
common stock has had limited trading.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
in our common stock has historically been thin. Because of the thinness of the market for our stock, the price of our common stock
may be subject to manipulation and may be volatile. This limited trading may adversely affect the liquidity of our common stock,
in terms of the number of shares that can be bought and sold at a given price. As a result, there could be a larger spread between
the bid and the ask prices of our common stock and investors may not be able to sell shares of our common stock when or at prices
they desire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fluctuations
in the price of our common stock, including as a result of actual or anticipated sales of shares by stockholders, may make our
common stock more difficult to resell.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price and trading volume of our common stock have been and may continue to be subject to significant fluctuations due not
only to general stock market conditions, but also to a change in sentiment in the market regarding the industry in which we operate,
our operations, business prospects or liquidity or this offering. During the period from January 1, 2015 to July 25, 2017, our
common stock has fluctuated from a low of $4.76 per share to a high of $11.40 per share. In addition to the risk factors discussed
in our periodic reports and in this prospectus supplement, the price and volume volatility of our common stock may be affected
by actual or anticipated sales of common stock by existing stockholders, including of shares purchased in this offering, whether
in the market or in subsequent public offerings. Stock markets in general have experienced extreme volatility recently that has
at times been unrelated to the operating performance of particular companies or industries. These broad market fluctuations may
adversely affect the trading price of our common stock, regardless of our operating results. As a result, these fluctuations in
the market price and trading volume of our common stock may make it difficult to predict the market price of our common stock
in the future, cause the value of your investment to decline and make it more difficult to resell our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
stockholders may experience further dilution if we issue additional shares of common stock in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional future issuances of common stock by us will reduce the percentage of our common stock owned by investors purchasing
shares in this offering who do not participate in such future issuances. In most circumstances stockholders will not be entitled
to vote on whether or not we issue additional common stock. In addition, depending on the terms and pricing of an additional offering
of our common stock and the value of our assets, our stockholders may experience dilution in both the book value and the market
value of their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
may be future sales or other dilution of our equity which may adversely affect the market price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not restricted from issuing additional common stock, including securities that are convertible into or exchangeable for, or
that represent the right to receive, common stock. We are offering 200,000 shares of common stock. The issuance of additional
shares of our common stock in this offering or other issuances of our common stock or convertible or other equity linked securities,
including options and warrants, or otherwise, in connection with capital raising transactions or for employee compensation or
other purposes will dilute the ownership interest of our common stockholders. As of July 25, 2017, we had 4,848,390 outstanding
shares of common stock, which excludes 368,000 shares of common stock issuable upon the exercise of outstanding stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our common stock or other equity-related securities in the public market could depress the
market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We
cannot predict the effect that future sales of our common stock or other equity-related securities would have on the market price
of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are not currently paying dividends and will likely continue not paying dividends for the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid or declared any cash dividends on our common stock. We currently intend to retain all available funds and any
future earnings to repay indebtedness and to fund the development and expansion of our business, and we do not anticipate paying
any cash dividends or repurchasing shares of our common stock in the foreseeable future. In addition, the terms of our existing
credit agreements restrict the payment of cash dividends on our common stock and the repurchase by us of our common stock. Any
future determination to pay dividends or to repurchase stock will be at the discretion of our board of directors and will depend
on our financial condition, results of operations, capital requirements, contractual restrictions and other factors that our board
of directors deems relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
in our rights plan and in Delaware law could make it more difficult for a third party to acquire us, discourage a takeover and
adversely affect existing stockholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors adopted in 1995 a common stock rights plan under which, if the rights issued thereunder are not redeemed by
the board and the board has not approved the acquisition by a prospective acquirer of 20% or more of our outstanding common stock,
the holders of such rights (other than such prospective acquirer) have the right, in effect, to purchase additional shares of
our common stock for each right held at a substantial discount from the market price of such stock, immediately preceding the
prospective acquirer&rsquo;s acquisition of such ownership (or announcement of an offer to acquire such ownership).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to the provisions of Section 203 of the Delaware General Corporation Law, which could prevent us from engaging
in a &ldquo;business combination&rdquo; with a 15% or greater stockholder for a period of three years from the date such person
acquired that status unless appropriate board or stockholder approvals are obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions could deter unsolicited takeovers or delay or prevent changes in our control or management, including transactions
in which stockholders might otherwise receive a premium for their shares over the then current market price. These provisions
may also limit the ability of stockholders to approve transactions that they may deem to be in their best interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could experience cost over-runs or delays in completing our expanded manufacturing facility or fail to access necessary funding
for the project.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, we have in place construction and equipment supply agreements for building and equipping our expanded Nisin manufacturing
facility; however, due to change orders, delays or other unforeseen events, actual project costs could exceed our current estimates.
In addition, completion of the project could be delayed due to factors outside our control, including construction or equipment
delivery delays or delays in obtaining FDA approvals for our novel mastitis treatment. Also, our ability to fund the completion
of the project depends on receipt of borrowed funds (which are subject to certain conditions, including our ongoing compliance
with financial covenants, and contingencies) and cash flow from future operations, which may not materialize or be available at
the needed levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_006"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds of this offering to us will be approximately $1,026,000, after deducting our estimated offering
expenses. We intend to use the net proceeds from this offering to increase our working capital reserves, which have been reduced
to low levels due to our expenditures on our Nisin production facilities (see &ldquo;Prospectus Supplement Summary &ndash; Our
Facilities Expansion&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_007"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRICE
RANGE OF OUR COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on The Nasdaq Capital Market under the symbol &ldquo;ICCC&rdquo;. The last reported sales price of our
common stock on The Nasdaq Capital Market on July 25, 2017 was $6.72 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for the periods indicated, the high and low sale prices for our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Year ending December 31, 2017</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6.14</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Third Quarter through July 25, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.54</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year ended December 31, 2016</B></FONT></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.46</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year ended December 31, 2015</B></FONT></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.99</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.95</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2017, there were approximately 817 holders of record of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on our common stock to date, and we do not expect to pay cash dividends in the foreseeable future.
Future dividend policy will depend on our earnings, capital requirements, financial condition, contractual restrictions, and other
factors considered relevant by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net tangible book value as of March 31, 2017 was approximately $20,106,000, or approximately $4.15 per share. Net tangible book
value per share is determined by dividing our total tangible assets (total assets less goodwill and intangible assets) less total
liabilities by the number of shares of our common stock outstanding as of March 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to our sale of 200,000 shares of our common stock in this offering at the public offering price of $5.25 per share,
and after deducting our estimated offering expenses of $24,000 payable by us, our as adjusted net tangible book value as of March
31, 2017 would have been approximately $21,132,000, or $4.19 per share. This represents an immediate increase in net tangible
book value of $0.04 per share to existing stockholders and immediate dilution in net tangible book value of $1.06 per share to
new investors participating in this offering at the public offering price. These calculations do not reflect the anticipated additional
indebtedness and spending on the Nisin production facility after March 31, 2017. The following table illustrates this dilution
on a per share basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Public offering price for one share of common stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Net tangible book value per share as of March 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Increase per share attributable to new investors</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.04</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">As adjusted net tangible book value per share after this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.19</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Dilution per share to new investors</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.06</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth above is based on 4,848,390 shares of common stock issued and outstanding as of March 31, 2017 and excludes
368,000 shares of common stock reserved for future issuance upon the exercise of outstanding options as of March 31, 2017 (of
which options with respect to 162,000 shares are currently exercisable).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above illustration of dilution per share to investors participating in this offering assumes no exercise of outstanding options
to purchase our common stock. The exercise of outstanding options having an exercise price less than the offering price will increase
dilution to new investors. In addition, we may choose to raise additional capital due to market conditions or strategic considerations
even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is
raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution
to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering shares of common stock directly to certain investors. We have arranged for the sale to such purchasers of the shares
of common stock offered pursuant to this prospectus supplement and the accompanying prospectus through one or more securities
purchase agreements between such purchasers and us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
obligation to issue and sell securities to purchasers is subject to the conditions set forth in the purchase agreements, which
may be waived by us in our discretion. A purchaser&rsquo;s obligation to purchase securities is subject to the conditions set
forth in the purchase agreement, as applicable, as well, which conditions may also be waived by a purchaser in its discretion.
In addition, we have agreed to indemnify the purchasers against certain liabilities, including liabilities under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently anticipate that the sale of up to 200,000 shares of our common stock offered in this prospectus supplement will be completed
on or about July 27, 2017. We estimate the total expenses of this offering payable by us will be approximately $24,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
form of securities purchase agreement we entered into with the purchasers will be included as an exhibit to our Current Report
on Form 8-K that will be filed with the SEC in connection with the consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price per share was determined based on negotiations with the purchasers based on current market factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_010"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of common stock offered by this prospectus supplement and the accompanying prospectus will be passed upon
for us by Pierce Atwood LLP of Portland, Maine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of ImmuCell Corporation as of and for the year ended December 31, 2016, incorporated in this Prospectus Supplement
by reference from the ImmuCell Corporation Annual Report on Form 10-K for the year ended December 31, 2016, have been audited
by RSM US LLP, an independent registered public accounting firm, as stated in their report thereon, incorporated herein by reference,
and have been incorporated in this Prospectus Supplement and Registration Statement in reliance upon such report and upon the
authority of such firm as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of ImmuCell Corporation as of and for the year ended December 31, 2015, incorporated in this Prospectus Supplement
by reference from the ImmuCell Corporation Annual Report on Form 10-K for the year ended December 31, 2016, have been audited
by Baker Newman &amp; Noyes LLC, an independent registered public accounting firm, as stated in their report thereon, incorporated
herein by reference, and have been incorporated in this Prospectus Supplement and Registration Statement in reliance upon such
report and upon the authority of such firm as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_012"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly and other reports and information with the SEC under the Securities Exchange Act of 1934, as amended, or
the Exchange Act. You may read and copy any of the reports, statements, or other information we file with the SEC at the SEC&rsquo;s
Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 at prescribed rates. Information on the operation of the Public
Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. The SEC maintains a website at <I>http://www.sec.gov</I>
that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. Our SEC
File Number for documents we filed under the Exchange Act is 001-12934. Our website address is <I>www.immucell.com</I>. We have
included our website address in this document as an inactive textual reference only, and the information contained in, or that
can be accessed through, our website does not constitute part of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_013"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to incorporate by reference the documents we file with them. This means that we can disclose important information
to you in this prospectus supplement by referring you to the documents that contain such information. These incorporated documents
contain important business and financial information about us that is not included in or delivered with this prospectus supplement
or the accompanying prospectus. The information incorporated by reference is considered to be part of this prospectus supplement
and accompanying prospectus, and later information filed with the SEC will update and supersede this information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference the documents listed below as well as any future filings made with the SEC under Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act (other than information deemed to have been furnished or not filed in accordance with the SEC&rsquo;s
rules) from the date of this prospectus supplement and prior to the termination of this offering:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the SEC on March 30, 2017;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the SEC on May 11, 2017;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Reports on Form 8-K filed with the SEC on February 10, 2017, March 2, 2017, March 8, 2017, May 11, 2017, June 16, 2017,
July 14, 2017, July 25, 2017 and July 27, 2017; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
definitive proxy statement on Schedule 14A filed on April 28, 2017 for our annual meeting of shareholders held on June 14, 2017.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may request, and we will provide to you at no cost, a copy of these filings by writing or telephoning our Corporate Secretary
at 56 Evergreen Drive, Portland, Maine, 04103, telephone number (207) 878-2770.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Options: NewSection; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">PROSPECTUS</FONT></P>
<P CLASS="Textflush" STYLE="text-align: right; margin: 12pt 0in 0pt; text-align: right; mso-style-name: Text_flush; font: 10pt/0pt TimesNewRomanPSStd-Regular; text-autospace: none; color: Black"> </P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Prospectus</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">IMMUCELL
CORPORATION</FONT></P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">$10,000,000.00</FONT></P>
<P CLASS="H1" STYLE=
"margin-top: 0in; mso-style-name: H1; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Common Stock</FONT></P>
<P CLASS="H1" STYLE=
"margin-top: 0in; mso-style-name: H1; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Warrants</FONT></P>
<P CLASS="H1" STYLE=
"margin-top: 0in; mso-style-name: H1; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Units</FONT></P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
From time to time, we may offer up to $10,000,000.00 of our common
stock, warrants to purchase common stock and/or units consisting of
common stock, warrants or any combination of these securities, in
one or more transactions.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We will provide specific terms of these offerings and securities in
one or more supplements to this prospectus. We may also authorize
one or more free writing prospectuses to be provided to you in
connection with these offerings. The prospectus supplement, and any
documents incorporated by reference, may also add, update or change
information contained in this prospectus. You should read this
prospectus, the applicable prospectus supplement, any documents
incorporated by reference and any related free writing prospectus
carefully before buying any of the securities being offered.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We may offer and sell these securities to or through one or more
underwriters, dealers and agents, or directly to purchasers, on a
continuous or delayed basis.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Our common stock is listed on the NASDAQ Capital Market under the
symbol &#8220;ICCC.&#8221; The applicable prospectus supplement
will contain information, where applicable, as to any other
listing, if any, of the securities covered by the applicable
prospectus supplement. The aggregate market value of our
outstanding common stock held by non-affiliates was approximately
$14,281,188 based on 3,055,034 shares of outstanding common stock,
of which 868,022 shares are held by affiliates, and a price of
$6.53 per share, which was the last reported sale price of our
common stock as quoted on NASDAQ Capital Market on November 3,
2015. We have not offered any securities pursuant to General
Instruction I.B.6 of Form S-3 during the prior 12 calendar month
period that ends on, and includes, the date of this prospectus.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
INVESTING IN OUR SECURITIES INVOLVES RISKS. YOU SHOULD REVIEW
CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING
&#8220;RISK FACTORS&#8221; CONTAINED IN THE APPLICABLE PROSPECTUS
SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND UNDER
SIMILAR HEADINGS IN THE OTHER DOCUMENTS THAT ARE INCORPORATED BY
REFERENCE INTO THIS PROSPECTUS.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THESE SECURITIES
OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</P>
<P CLASS="Textflush" ALIGN="center" STYLE=
"text-align: center; mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The date of this prospectus is November 10, 2015</P>
<P CLASS="LRH" STYLE=
"margin: 0in; margin-bottom: .0001pt; page-break-after: always; border-bottom: 1px solid; mso-style-name: LRH; margin-top: 10.0pt; margin-right: 0in; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
&nbsp;</P>
<P CLASS="H1" STYLE=
"margin-bottom: 10.0pt; mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">TABLE OF
CONTENTS</FONT></P>
<TABLE CLASS="MsoNormalTable" BORDER="0" CELLSPACING="0"
CELLPADDING="0" WIDTH="100%" STYLE=
"width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0px; margin: 0 auto;">
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB"><A HREF="#bp1">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">1</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG="EN-GB"><A HREF="#bp2">ABOUT THIS PROSPECTUS</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">1</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG="EN-GB"><A HREF="#bp3">ABOUT IMMUCELL CORPORATION</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">2</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG="EN-GB"><A HREF="#bp4">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">3</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB"><A HREF="#bp5">INCORPORATION OF INFORMATION BY REFERENCE</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">4</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG="EN-GB"><A HREF="#bp6">RISK FACTORS</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">5</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB"><A HREF="#bp7">DESCRIPTION OF SECURITIES WE MAY OFFER</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">5</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB"><A HREF="#bp8">DESCRIPTION OF COMMON STOCK</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">6</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB"><A HREF="#bp9">DESCRIPTION OF WARRANTS</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">9</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB"><A HREF="#bp10">DESCRIPTION OF UNITS</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">11</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG="EN-GB"><A HREF="#bp11">USE OF PROCEEDS</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">12</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG="EN-GB"><A HREF="#bp12">PLAN OF DISTRIBUTION</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">12</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG="EN-GB"><A HREF="#bp13">LEGAL MATTERS</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">15</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB"><A HREF="#bp14">EXPERTS</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: white; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">15</FONT></FONT></P>
</TD>
</TR>
<TR>
<TD WIDTH="89%" VALIGN="bottom" STYLE=
"width: 89.4%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" STYLE=
"line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB"><A HREF="#bp15">INTERESTS OF NAMED EXPERTS AND COUNSEL</A></FONT></FONT></P>
</TD>
<TD WIDTH="1%" VALIGN="bottom" STYLE=
"width: 1.68%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="NoParagraphStyle" STYLE=
'line-height: normal; mso-style-name: "\[No Paragraph Style\]"; margin: 0in; margin-bottom: .0001pt; text-autospace: none; font-size: 12.0pt; font-family: MinionPro-Regular; color: black;'>
<FONT STYLE=
"font-family: TimesNewRomanPSStd-Bold; color: windowtext;">&nbsp;</FONT></P>
</TD>
<TD WIDTH="8%" VALIGN="bottom" STYLE=
"width: 8.92%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<P CLASS="Tbody" ALIGN="center" STYLE=
"text-align: center; line-height: normal; padding-bottom: 3px; mso-style-name: Tbody; margin-top: 0in; margin-right: 0in; margin-bottom: .0001pt; margin-left: 10.0pt; text-indent: -10.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bold0" STYLE=
"mso-style-name: bold; font-weight: bold;"><FONT LANG=
"EN-GB">15</FONT></FONT></P>
</TD>
</TR>
</TABLE>
<P CLASS="RRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: RRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
i</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp1"></A>
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Some of the statements in this prospectus and in any prospectus
supplement we may file constitute &#8220;forward-looking
statements&#8221; within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These statements relate to future events concerning
our business and to our future revenues, operating results and
financial condition. In some cases, you can identify
forward-looking statements by terminology such as
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221;
&#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221;
&#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221;
&#8220;intend,&#8221; &#8220;believe,&#8221;
&#8220;estimate,&#8221; &#8220;target,&#8221;
&#8220;forecast,&#8221; &#8220;predict,&#8221;
&#8220;project&#8221;, &#8220;propose,&#8221;
&#8220;potential,&#8221; or &#8220;continue,&#8221; or the negative
of those terms or other comparable terminology.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Any forward looking statements contained in this prospectus or any
prospectus supplement are only estimates or predictions of future
events based on information currently available to our management
and management&#8217;s current beliefs about the potential outcome
of future events. Whether these future events will occur as
management anticipates, whether we will achieve our business
objectives, and whether our revenues, operating results or
financial condition will be sustained or improve in future periods
are subject to numerous risks. There are a number of important
factors that could cause actual results to differ materially from
the results anticipated by these forward-looking statements. These
important factors include those that we discuss under the heading
&#8220;Risk Factors&#8221; and in other sections of our Annual
Report on Form 10-K for the year ended December 31, 2014 and our
Form 10-Q for the quarterly period ended June 30, 2015, all filed
with the Securities and Exchange Commission (&#8220;SEC&#8221;), as
well as in our other reports filed from time to time with the SEC
that are incorporated by reference into this prospectus. You should
read these factors and the other cautionary statements made in this
prospectus and in the documents we incorporate by reference into
this prospectus as being applicable to all related forward-looking
statements wherever they appear in this prospectus or the documents
we incorporate by reference into this prospectus. If one or more of
these factors materialize, or if any underlying assumptions prove
incorrect, our actual results, performance or achievements may vary
materially from any future results, performance or achievements
expressed or implied by these forward-looking statements. We
undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp2"></A>
ABOUT THIS PROSPECTUS</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
This document is called a prospectus and is part of a registration
statement that we have filed with the SEC, using a
&#8220;shelf&#8221; registration process. Under this shelf
registration process, we may, from time to time, offer shares of
our common stock, warrants to purchase common stock and/or units
consisting of common stock, warrants or any combination of these
securities, in one or more transactions and in amounts we will
determine from time to time, up to a total dollar amount of
$10,000,000.00.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
This prospectus provides you with a general description of the
securities we may offer. Each time we offer a type or series of
securities described in this prospectus, we will provide a
prospectus supplement or information that is incorporated by
reference into this prospectus, containing more specific
information about the terms of the securities that we are offering.
We may also authorize one or more free writing prospectuses to be
provided to you that may contain material information relating to
these offerings and securities. This prospectus, together with
applicable prospectus supplements, any information incorporated by
reference and any related free writing prospectuses, includes all
material information relating to these offerings and securities. We
may also add, update or change in the prospectus supplement any of
the information contained in this prospectus or in the documents
that we have incorporated by reference into this prospectus,
including, without limitation, a discussion of any risk factors or
other special considerations that apply to these offerings or
securities or the specific plan of distribution. If there is any
inconsistency between the information in this prospectus and a
prospectus supplement or information incorporated by reference
having a later date, you should rely on the information in that
prospectus supplement or incorporated information having a later
date. We urge you to read carefully this prospectus, any applicable
prospectus supplement and any related free writing prospectus,
together with the information incorporated herein by reference as
described under the heading &#8220;Where You Can Find More
Information,&#8221; before buying any of the securities being
offered.</P>
<P CLASS="LRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: LRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
1</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
You should rely only on the information we have provided or
incorporated by reference in this prospectus, any applicable
prospectus supplement and any related free writing prospectus. We
have not authorized anyone to provide you with different
information. No dealer, salesperson or other person is authorized
to give any information or to represent anything not contained in
this prospectus, any applicable prospectus supplement or any
related free writing prospectus.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Neither the delivery of this prospectus nor any sale made under it
implies that there has been no change in our affairs or that the
information in this prospectus is correct as of any date after the
date of this prospectus. You should assume that the information in
this prospectus, any applicable prospectus supplement or any
related free writing prospectus is accurate only as of the date on
the front of the document and that any information we have
incorporated by reference is accurate only as of the date of the
document incorporated by reference, regardless of the time of
delivery of this prospectus, any applicable prospectus supplement
or any related free writing prospectus, or any sale of a
security.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
This prospectus contains summaries of certain provisions contained
in some of the documents described herein, but reference is made to
the actual documents for complete information. All of the summaries
are qualified in their entirety by the actual documents. Copies of
some of the documents referred to herein have been filed, will be
filed or will be incorporated by reference as exhibits to the
registration statement of which this prospectus is a part, and you
may obtain copies of those documents as described below under
&#8220;Where You Can Find More Information&#8221;. THIS PROSPECTUS
MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES, UNLESS IT IS
ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
In this prospectus, unless the context otherwise requires,
references to &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;
or similar terms, as well as references to &#8220;ImmuCell&#8221;
or the &#8220;Company&#8221;, refer to ImmuCell Corporation.</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp3"></A>
ABOUT IMMUCELL CORPORATION</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We are a growing animal health company whose purpose is to create
scientifically-proven and practical products that result in a
measurable economic impact on animal health and productivity in the
dairy and beef industries. We were originally incorporated in Maine
in 1982 and reincorporated in Delaware in 1987, in conjunction with
our initial public offering of common stock. We have developed
products that provide significant, immediate immunity to newborn
dairy and beef cattle and are in the late stages of developing a
new product that addresses mastitis, the most significant cause of
economic loss to the dairy industry. Across all product lines, our
product sales during the year ended December 31, 2014 increased by
26%, or $1,590,000, to $7,597,000 from $6,007,000 in 2013, and
gross margins as a percentage of product sales were 59% in 2014, as
compared to 51% during 2013.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Growth in sales of our lead product, <FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">First
Defense</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>
and related product line extensions, is driving the increase in our
total product sales. Sales of <FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">First
Defense</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>,
and related product line extensions aggregated 91.6% and 91.4% of
our total product sales during the years ended December 31, 2014
and 2013, respectively. Sales of <FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">First
Defense</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>
and related product line extensions increased by 27%, 14% and 5%
during the years ended December 31, 2014, 2013 and 2012,
respectively, in comparison to the prior years. <FONT CLASS="Bold"
STYLE="mso-style-name: Bold; font-weight: bold;">First
Defense</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>
is manufactured from hyperimmune cows&#8217; colostrum (the milk
that a cow produces immediately after giving birth) utilizing our
proprietary vaccine and milk protein purification technologies. The
target disease, bovine enteritis (calf scours), causes diarrhea and
dehydration in newborn calves and often leads to serious sickness
and even death. <FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">First
Defense</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>
is the only orally delivered scours preventive product on the
market for calves that is licensed by the U.S. Department of
Agriculture (USDA) with claims against <FONT CLASS="Italic" STYLE=
"mso-style-name: Italic; font-style: italic;">E. coli</FONT> K99
and coronavirus (two leading causes of scours). <FONT CLASS="Bold"
STYLE="mso-style-name: Bold; font-weight: bold;">First
Defense</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>
provides bovine antibodies that newborn calves need but are unable
to produce on their own immediately after birth. Our milk antibody
products provide <FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Immediate
Immunity</FONT>&#8482; during the first few critical days of life
when calves need this protection most. Studies have shown that
calves that scour are more susceptible to other diseases later in
life and under-perform calves that do not contract scours.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The majority of our product development budget from 2000 through
2015 has been focused on the development of <FONT CLASS="Bold"
STYLE="mso-style-name: Bold; font-weight: bold;">Mast
Out</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>,
a Nisin-based intramammary treatment of subclinical mastitis in
lactating dairy cows. During the fifteen-year period that began on
January 1, 2000 (the year we began the development of <FONT CLASS=
"Bold" STYLE="mso-style-name: Bold; font-weight: bold;">Mast
Out</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>)
and ended on December 31, 2014, we invested the aggregate of
approximately $11,032,000 in the development of <FONT CLASS="Bold"
STYLE="mso-style-name: Bold; font-weight: bold;">Mast
Out</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>.
This estimated allocation to <FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Mast
Out</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>
reflects only direct expenditures and includes no allocation of
product development or administrative overhead expenses.
Approximately $2,891,000 of this investment was offset by product
licensing revenues and grant income related to <FONT CLASS="Bold"
STYLE="mso-style-name: Bold; font-weight: bold;">Mast
Out</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>.
Nisin is an antibacterial peptide that has been</P>
<P CLASS="RRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: RRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
2</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
demonstrated in clinical studies to be an effective aid in the
reduction of mastitis-causing organisms in dairy cows. Mastitis is
a very common infection in dairy cows that results in inflammation
of the mammary gland. Because dairy producers are required to
discard milk for a period during and after treatment with all
currently marketed mastitis treatment products due to concerns
about antibiotic residue in milk, it is generally current practice
to only treat mastitis when the disease has progressed to the
clinical stage where the milk from an infected cow cannot be sold.
We believe that <FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Mast
Out</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>
could revolutionize the way that mastitis is treated by making
earlier treatment of subclinically infected cows economically
feasible by not requiring a milk discard during, or for a period of
time after, treatment. No other FDA-approved mastitis treatment
product on the market can offer this value proposition. Commercial
introduction of <FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Mast
Out</FONT><FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>
in the United States is subject to approval of our New Animal Drug
Application by the U.S. Food and Drug Administration&#8217;s Center
for Veterinary Medicine (FDA), which approval cannot be assured.
Foreign regulatory approvals would be required for sales in key
markets outside of the United States, which would involve some
similar and some different requirements.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Our principal executive offices are located at 56 Evergreen Drive,
Portland, ME 04103. Our telephone number is (207) 878-2770. Our
website is located at <FONT CLASS="italic0" STYLE=
"mso-style-name: italic; font-style: italic;">www.immucell.com</FONT>.
Information contained on, or that can be accessed through, our
website is not part of this prospectus.</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp4"></A>
WHERE YOU CAN FIND ADDITIONAL INFORMATION</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We have filed with the SEC a registration statement on Form S-3
under the Securities Act of 1933, as amended (&#8220;Securities
Act&#8221;), with respect to the securities covered by this
prospectus. This prospectus, which is a part of the registration
statement, does not contain all of the information set forth in the
registration statement or the exhibits and schedules filed
therewith. For further information with respect to us and the
securities covered by this prospectus, please see the registration
statement and the exhibits filed with the registration statement. A
copy of the registration statement and the exhibits filed with the
registration statement may be inspected without charge at the
Public Reference Room maintained by the SEC, located at 100 F
Street, N.E., Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330 for more information about the operation of the
Public Reference Room. The SEC also maintains a website that
contains reports, proxy and information statements and other
information regarding registrants that file electronically with the
SEC. The address of the website is <FONT CLASS="Italic" STYLE=
"mso-style-name: Italic; font-style: italic;">http://www.sec.gov</FONT>.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We are subject to the information and periodic reporting
requirements of the Securities Exchange Act of 1934, as amended
(the &#8220;Exchange Act&#8221;) and, in accordance therewith, we
file periodic reports, proxy statements and other information with
the SEC. Such periodic reports, proxy statements and other
information are available for inspection and copying at the Public
Reference Room and website of the SEC referred to above. We
maintain a website at <FONT CLASS="italic0" STYLE=
"mso-style-name: italic; font-style: italic;">www.immucell.com</FONT>.
You may access our Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q, Current Reports on Form 8-K and amendments to those
reports filed pursuant to Sections 13(a) or 15(d) of the Exchange
Act with the SEC free of charge at our website as soon as
reasonably practicable after such material is electronically filed
with, or furnished to, the SEC. Our website and the information
contained on that site, or connected to that site, are not
incorporated into and are not a part of this prospectus.</P>
<P CLASS="LRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: LRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
3</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp5"></A>
INCORPORATION OF INFORMATION BY REFERENCE</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The SEC allows us to &#8220;incorporate by reference&#8221; the
information we file with it, which means that we can disclose
important information to you by referring you to those documents.
The information we incorporate by reference is an important part of
this prospectus, and certain information that we will later file
with the SEC will automatically update and supersede this
information. We incorporate by reference the documents listed
below, as well as any future filings made with the SEC under
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act from the
date of the initial registration statement and prior to the
effectiveness of this registration statement, and any filings made
after the date of this prospectus until we sell all of the
securities under this prospectus, except that we do not incorporate
any document or portion of a document that was furnished and deemed
by the rules of the SEC not to have been filed:</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
Our Annual Report on Form 10-K for the fiscal year ended December
31, 2014, filed with the SEC on March 26, 2015;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
Our Quarterly Reports on Form 10-Q for the quarters ended March 31,
2015 and June 30, 2015, filed with the SEC on May 12, 2015 and
August 13, 2015, respectively;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE="mso-style-name: bullet;"><FONT STYLE=
"letter-spacing: -.05pt;">&#8226;</FONT></FONT><FONT CLASS="bullet"
STYLE="mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt; letter-spacing: -.05pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
<FONT STYLE="letter-spacing: -.05pt;">Our Current Reports on Form
8-K filed with the SEC on February 11, 2015, February 25, 2015,
April 15, 2015, May 12, 2015, June 12, 2015, July 8, 2015, August
13, 2015, and September 24, 2015; and</FONT></P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
Our definitive proxy statement on Schedule 14A filed on April 24,
2015 for our annual meeting of shareholders held on June 11,
2015.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Additionally, all reports and other documents subsequently filed by
us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange
Act after (i) the date of the initial registration statement and
prior to effectiveness of the registration statement; and (ii) the
date of this prospectus and prior to the termination or completion
of this offering, shall be deemed to be incorporated by reference
in this prospectus and to be part hereof from the date of filing of
such reports and other documents. Any information that we
subsequently file with the SEC that is incorporated by reference as
described above will automatically update and supersede any
previous information that is part of this prospectus.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We hereby undertake to provide without charge to each person,
including any beneficial owner, to whom a copy of this prospectus
is delivered, upon written or oral request of any such person, a
copy of any and all of the information that has been or may be
incorporated by reference in this prospectus, other than exhibits
to such documents. Requests for such copies should be directed to
our Corporate Secretary at 56 Evergreen Drive, Portland, ME 04103.
Our telephone number is (207) 878-2770.</P>
<P CLASS="RRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: RRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
4</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp6"></A>
RISK FACTORS</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Investing in our securities involves significant risks. You should
review carefully the risks and uncertainties described under the
heading &#8220;Risk Factors&#8221; contained in, or incorporated
into, the applicable prospectus supplement and any related free
writing prospectus, and under similar headings in the other
documents that are incorporated by reference herein or therein.
Each of the referenced risks and uncertainties could adversely
affect our business, operating results and financial condition, as
well as adversely affect the value of an investment in our
securities. Additional risks not known to us or that we believe are
immaterial may also adversely affect our business, operating
results and financial condition and the value of an investment in
our securities.</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp7"></A>
DESCRIPTION OF SECURITIES WE MAY OFFER</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We may offer, from time to time, shares of our common stock,
warrants to purchase common stock or units comprised of shares of
common stock, warrants, or a combination of these securities, under
this prospectus at prices and on terms to be determined by market
conditions at the time of offering. This prospectus provides you
with a general description of the securities we may offer. See
&#8220;Description of Common Stock,&#8221; &#8220;Description of
Warrants,&#8221; and &#8220;Description of Units&#8221; below. Each
time we offer a type or series of securities, we will provide a
prospectus supplement that will describe the specific amounts,
prices and other important terms of the securities.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The prospectus supplement and any related free writing prospectus
also may supplement or, as applicable, add, update or change
information contained in this prospectus or in documents we have
incorporated by reference. However, no prospectus supplement or
free writing prospectus will offer a security that is not
registered and described in this prospectus at the time of the
effectiveness of the registration statement of which this
prospectus is a part.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The terms of any particular offering, the initial offering price
and the net proceeds to us will be contained in the prospectus
supplement, information incorporated by reference or free writing
prospectus relating to such offering.</P>
<P CLASS="LRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: LRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
5</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp8"></A>
DESCRIPTION OF COMMON STOCK</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The description below of our common stock and provisions of our
certificate of incorporation and bylaws are summaries and are
qualified by reference to the certificate of incorporation and the
bylaws. These documents are filed as exhibits to the registration
statement of which this prospectus is a part.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Our authorized capital stock consists of 8,000,000 shares of common
stock. As of November 3, 2015, there were 3,055,034 shares of
common stock outstanding.</P>
<P CLASS="H2" STYLE=
"mso-style-name: H2; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Common Stock</FONT></P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The holders of common stock are entitled to receive ratably
dividends, if any, as may be declared from time to time by the
Board of Directors out of funds legally available for that purpose.
In the event of our liquidation, dissolution or winding up, whether
voluntary or involuntary, the holders of common stock are entitled
to share ratably in all assets remaining after payment of or
provision for liabilities. The common stock has no preemptive or
conversion rights or other subscription rights. There are no
redemption or sinking fund provisions applicable to the common
stock. All outstanding shares of common stock are fully paid and
nonassessable, and the shares of common stock to be issued upon the
closing of this offering will be fully paid and nonassessable.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The holders of common stock are entitled to one vote per share on
all matters to be voted upon by the shareholders. There is no
cumulative voting.</P>
<P CLASS="H2" STYLE=
"mso-style-name: H2; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Effect of Certain
Provisions of our Certificate of Incorporation, Bylaws and Common
Stock Rights Plan</FONT></P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Provisions of our certificate of incorporation, our bylaws, our
Common Stock Rights Plan or Delaware law may discourage, delay or
prevent a merger, acquisition or other change in control that
stockholders may consider favorable, including transactions in
which stockholders might otherwise receive a premium for their
shares of our common stock. These provisions may also prevent or
frustrate attempts by our stockholders to replace or remove our
management. These provisions include:</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
limitations on the removal of directors; advance notice
requirements for stockholder proposals and nominations;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the ability of our Board of Directors to alter or repeal our
bylaws;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the ability of our Board of Directors to refuse to redeem rights
issued under our Common Stock Rights Plan or otherwise to limit or
suspend its operation that would work to dilute the stock ownership
of a potential hostile acquirer, likely preventing acquisitions
that have not been approved by our Board of Directors; and</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
Section 203 of the Delaware General Corporation Law, which
prohibits a publicly-held Delaware corporation from engaging in a
business combination with an interested stockholder (generally
defined as a person which together with its affiliates owns, or
within the last three years has owned, 15% of our voting stock, for
a period of three years after the date of the transaction in which
the person became an interested stockholder) unless the business
combination is approved in a prescribed manner.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The existence of the foregoing provisions and anti-takeover
measures could depress the trading price of our common stock or
limit the price that investors might be willing to pay in the
future for shares of our common stock. They could also deter
potential acquirers of our Company, thereby reducing the likelihood
of obtaining a premium for our common stock in an acquisition.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
These provisions, summarized below, are expected to discourage
coercive takeover practices and inadequate takeover bids and to
promote stability in our management. These provisions are also
designed to encourage persons seeking to acquire control of us to
first negotiate with our Board of Directors.</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
<U>Shareholder Meetings</U>.&#8195;Our bylaws provide that a
special meeting of shareholders may be called only by the President
or by the Board of Directors or by shareholders holding a majority
of the outstanding shares of our common stock.</P>
<P CLASS="RRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: RRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
6</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
<U>Requirements for Advance Notification of Shareholder Nominations
and Proposals</U>.&#8195;Our bylaws establish advance notice
procedures with respect to shareholder proposals and the nomination
of candidates for election as directors, other than nominations
made by or at the direction of our Board of Directors or a
committee of the Board of Directors.</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
<U>Board of Directors Vacancies</U>.&#8195;Under our bylaws, any
vacancy on the Board of Directors, including a vacancy resulting
from an enlargement of the Board of Directors, may only be filled
by vote of a majority of the remaining directors. Any director may
be removed by vote of the holders of a majority of the outstanding
shares of our common stock. The limitations on the removal of
directors and filling of vacancies would have the effect of making
it more difficult for a third party to acquire control of us, or of
discouraging a third party from acquiring control of us.</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
<U>Board of Directors Size</U>.&#8195;Within the range specified by
our bylaws, our Board of Directors determines the size of our Board
of Directors and may create new directorships and elect new
directors, which may enable an incumbent Board of Directors to
maintain control by adding directors.</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
<U>Indemnification</U>.&#8195;Our certificate of incorporation and
our bylaws, as amended, provide that we will indemnify officers and
directors against losses as they incur in investigations and legal
proceedings resulting from their services to us, which may include
service in connection with takeover defense measures.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
In September 1995, our Board of Directors adopted a Common Stock
Rights Plan and declared a dividend of one common share purchase
right (a &#8220;Right&#8221;) for each of the then outstanding
shares of the common stock of the Company. Each Right entitles the
registered holder to purchase from the Company one share of common
stock at an initial purchase price of $70.00 per share, subject to
adjustment. The description and terms of the Rights are set forth
in a Rights Agreement between the Company and American Stock
Transfer &amp; Trust Company, LLC, as Rights Agent.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The Rights (as amended) become exercisable and transferable apart
from the common stock upon the earlier of i) 10 days following a
public announcement that a person or group (Acquiring Person) has,
without the prior consent of the Continuing Directors (as such term
is defined in the Rights Agreement), acquired beneficial ownership
of 20% or more of the outstanding common stock or ii) 10 days
following commencement of a tender offer or exchange offer the
consummation of which would result in ownership by a person or
group of 20% or more of the outstanding common stock (the earlier
of such dates being called the Distribution Date).</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Upon the Distribution Date, the holder of each Right not owned by
the Acquiring Person would be entitled to purchase common stock at
a discount to the initial purchase price of $70.00 per share,
effectively equal to one half of the market price of a share of
common stock on the date the Acquiring Person becomes an Acquiring
Person. If, after the Distribution Date, the Company should
consolidate or merge with any other entity and the Company were not
the surviving company, or, if the Company were the surviving
company, all or part of the Company&#8217;s common stock were
changed or exchanged into the securities of any other entity, or if
more than 50% of the Company&#8217;s assets or earning power were
sold, each Right would entitle its holder to purchase, at the
Rights&#8217; then-current purchase price, a number of shares of
the acquiring company&#8217;s common stock having a market value at
that time equal to twice the Right&#8217;s exercise price.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
At any time after a person or group becomes an Acquiring Person and
prior to the acquisition by such person or group of 50% or more of
the outstanding common stock, the Board of Directors of the Company
may exchange the Rights (other than Rights owned by such person or
group which have become void), in whole or in part, at an exchange
ratio of one share of common stock per Right (subject to
adjustment). At any time prior to 14 days following the date that
any person or group becomes an Acquiring Person (subject to
extension by the Board of Directors), the Board of Directors of the
Company may redeem the then outstanding Rights in whole, but not in
part, at a price of $0.005 per Right, subject to adjustment.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
On June 8, 2005, our Board of Directors voted to authorize an
amendment of the Rights Agreement to extend the Final Expiration
Date by an additional three years, to September 19, 2008. As of
June 30, 2005, we entered into an amendment to the Rights Agreement
with the Rights Agent reflecting such extension. On June 6, 2008
our Board of Directors voted to authorize an amendment of the
Rights Agreement to extend the Final Expiration Date by an
additional three years, to September 19, 2011, and to increase the
ownership threshold for determining</P>
<P CLASS="LRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: LRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
7</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
&#8220;Acquiring Person&#8221; status from 15% to 18%. As of June
30, 2008, we entered into an amendment to the Rights Agreement with
the Rights Agent reflecting such extension and threshold increase.
On August 5, 2011, our Board of Directors voted to authorize
amendments of the Rights Agreement to extend the Final Expiration
Date by an additional three years to September 19, 2014 and to
increase the ownership threshold for determining &#8220;Acquiring
Person&#8221; status from 18% to 20%. As of August 9, 2011, we
entered into an amendment to the Rights Agreement with the Rights
Agent reflecting such extension and threshold increase. On June 10,
2014, our Board of Directors voted to authorize an amendment to the
Rights Agreement to extend the final expiration date by an
additional three years to September 19, 2017. As of June 16, 2014,
we entered into an amendment to the Rights Agreement with the
Rights Agent reflecting such extension. As of April 15, 2015, we
entered into an amendment to the Rights Agreement with the Rights
Agent deleting the provisions requiring that redemptions of the
Rights, waivers or consents avoiding &#8220;Acquiring Person&#8221;
status or certain amendments to the Rights Agreement be approved by
&#8220;Continuing Directors&#8221;. No other changes have been made
to the terms of the Rights or the Rights Agreement.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Our Board of Directors believes that there is some risk that the
potential value of the Mast Out<FONT CLASS="superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>
product development initiative is not fairly reflected in the
market price of our common stock, as it fluctuates from time to
time, and that opportunistic buyers could take advantage of that
disparity to the detriment of our stockholders. If this were to
happen and result in a potential threat through an unsolicited
acquisition effort or otherwise, our Board of Directors feels that
the Common Stock Rights Plan could enhance stockholder value by
providing management with negotiating leverage.</P>
<P CLASS="H2" STYLE=
"mso-style-name: H2; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Listing</FONT></P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Our common stock is listed on the NASDAQ Capital Market under the
symbol &#8220;ICCC&#8221;.</P>
<P CLASS="H2" STYLE=
"mso-style-name: H2; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;">
<FONT CLASS="Bold" STYLE=
"mso-style-name: Bold; font-weight: bold;">Transfer Agent and
Registrar</FONT></P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The transfer agent and registrar for our common stock is American
Stock Transfer &amp; Trust Company, LLC.</P>
<P CLASS="RRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: RRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
8</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp9"></A>
DESCRIPTION OF WARRANTS</P>
<P CLASS="H3" STYLE=
"mso-style-name: H3; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-BoldIt; color: black; font-weight: bold; font-style: italic;">
<FONT CLASS="Italic" STYLE=
"mso-style-name: Italic; font-style: italic;"><FONT STYLE=
"font-weight: normal;">General</FONT></FONT></P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We may issue warrants to purchase common stock. We may issue the
warrants independently or together with any underlying securities,
and the warrants may be attached to or separate from the underlying
securities. We may also issue a series of warrants under a separate
warrant agreement to be entered into between us and a warrant
agent. The warrant agent will act solely as our agent in connection
with the warrants of such series and will not assume any obligation
or relationship of agency for or with holders or beneficial owners
of warrants.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The following description is a summary of selected provisions
relating to the warrants that we may issue. The summary is not
complete. If warrants are offered in the future, a prospectus
supplement, information incorporated by reference or a free writing
prospectus, as applicable, will explain the particular terms of
those securities and the extent to which these general provisions
may apply. The specific terms of the warrants as described in a
prospectus supplement, information incorporated by reference, or
free writing prospectus will supplement and, if applicable, may
modify or replace the general terms described in this section.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
This summary and any description of warrants in the applicable
prospectus supplement, information incorporated by reference or
free writing prospectus is subject to and is qualified in its
entirety by reference to all the provisions of any specific warrant
document or agreement. We will file each of these documents, as
applicable, with the SEC and incorporate them by reference as an
exhibit to the registration statement of which this prospectus is a
part on or before the time we issue a series of warrants. See
&#8220;Where You Can Find Additional Information&#8221; and
&#8220;Incorporation of Information by Reference&#8221; above for
information on how to obtain a copy of a warrant document when it
is filed.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
When we refer to a series of warrants, we mean all warrants issued
as part of the same series under the applicable warrant
agreement.</P>
<P CLASS="H3" STYLE=
"mso-style-name: H3; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-BoldIt; color: black; font-weight: bold; font-style: italic;">
<FONT CLASS="Italic" STYLE=
"mso-style-name: Italic; font-style: italic;"><FONT STYLE=
"font-weight: normal;">Terms</FONT></FONT></P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The applicable prospectus supplement, information incorporated by
reference or free writing prospectus, may describe the terms of any
warrants that we may offer, including, but not limited to, the
following:</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the title of the warrants;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the total number of warrants;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the price or prices at which the warrants will be issued;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the price or prices at which the warrants may be exercised;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the currency or currencies that investors may use to pay for the
warrants;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the date on which the right to exercise the warrants will commence
and the date on which the right will expire;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
whether the warrants will be issued in registered form or bearer
form;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
information with respect to book-entry procedures, if any;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
if applicable, the minimum or maximum amount of warrants that may
be exercised at any one time;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
if applicable, the number of warrants issued with each underlying
security;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
if applicable, the date on and after which the warrants and the
related underlying common stock will be separately
transferable;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
if applicable, a discussion of material United States federal
income tax considerations;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
if applicable, the terms of redemption of the warrants;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the identity of the warrant agent, if any;</P>
<P CLASS="LRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: LRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
9</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the procedures and conditions relating to the exercise of the
warrants; and</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
any other terms of the warrants, including terms, procedures and
limitations relating to the exchange and exercise of the
warrants.</P>
<P CLASS="H3" STYLE=
"mso-style-name: H3; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-BoldIt; color: black; font-weight: bold; font-style: italic;">
<FONT CLASS="Italic" STYLE=
"mso-style-name: Italic; font-style: italic;"><FONT STYLE=
"font-weight: normal;">Warrant Agreement</FONT></FONT></P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We may issue the warrants in one or more series under one or more
warrant agreements, each to be entered into between us and a bank,
trust company or other financial institution as warrant agent. We
may add, replace or terminate warrant agents from time to time. We
may also choose to act as our own warrant agent.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The warrant agent under a warrant agreement will act solely as our
agent in connection with the warrants issued under that agreement.
Any holder of warrants may, without the consent of any other
person, enforce by appropriate legal action, on its own behalf, its
right to exercise those warrants in accordance with their
terms.</P>
<P CLASS="H3" STYLE=
"mso-style-name: H3; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-BoldIt; color: black; font-weight: bold; font-style: italic;">
<FONT CLASS="Italic" STYLE=
"mso-style-name: Italic; font-style: italic;"><FONT STYLE=
"font-weight: normal;">Form, Exchange and
Transfer</FONT></FONT></P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We may issue the warrants in registered form or bearer form.
Warrants issued in registered form, i.e., book-entry form, will be
represented by a global security registered in the name of a
depository, which will be the holder of all the warrants
represented by the global security. Those investors who own
beneficial interests in a global warrant will do so through
participants in the depository&#8217;s system, and the rights of
these indirect owners will be governed solely by the applicable
procedures of the depository and its participants. In addition, we
may issue warrants in non-global form, i.e., bearer form. If any
warrants are issued in non-global form, warrant certificates may be
exchanged for new warrant certificates of different denominations,
and holders may exchange, transfer or exercise their warrants at
the warrant agent&#8217;s office or any other office indicated in
the applicable prospectus supplement, information incorporated by
reference or free writing prospectus.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Prior to the exercise of their warrants, holders of warrants
exercisable for shares of common stock will not have any rights of
holders of common stock purchasable upon such exercise and will not
be entitled to dividend payments, if any, or voting rights of the
common stock purchasable upon such exercise.</P>
<P CLASS="H3" STYLE=
"mso-style-name: H3; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-BoldIt; color: black; font-weight: bold; font-style: italic;">
<FONT CLASS="Italic" STYLE=
"mso-style-name: Italic; font-style: italic;"><FONT STYLE=
"font-weight: normal;">Exercise of Warrants</FONT></FONT></P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
A warrant will entitle the holder to purchase for cash an amount of
common stock at an exercise price that will be stated in, or that
will be determinable as described in, the applicable prospectus
supplement, information incorporated by reference or free writing
prospectus. Warrants may be exercised at any time up to the close
of business on the expiration date set forth in the applicable
offering material. After the close of business on the expiration
date, unexercised warrants will become void. Warrants may be
redeemed as set forth in the applicable offering material.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Warrants may be exercised as set forth in the applicable offering
material. Upon receipt of payment and the warrant certificate
properly completed and duly executed at the corporate trust office
of the warrant agent or any other office indicated in the
applicable offering material, we will forward, as soon as
practicable, the common stock purchasable upon such exercise. If
less than all of the warrants represented by such warrant
certificate are exercised, a new warrant certificate will be issued
for the remaining warrants.</P>
<P CLASS="RRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: RRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
10</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp10"></A>
DESCRIPTION OF UNITS</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We may issue units composed of any combination of our common stock
and warrants. We will issue each unit so that the holder of the
unit is also the holder of each security included in the unit. As a
result, the holder of a unit will have the rights and obligations
of a holder of each included security. The unit agreement under
which a unit is issued may provide that the securities included in
the unit may not be held or transferred separately, at any time or
at any time before a specified date.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The following description is a summary of selected provisions
relating to units that we may offer. The summary is not complete.
When units are offered in the future, a prospectus supplement,
information incorporated by reference or a free writing prospectus,
as applicable, will explain the particular terms of those
securities and the extent to which these general provisions may
apply. The specific terms of the units as described in a prospectus
supplement, information incorporated by reference, or free writing
prospectus will supplement and, if applicable, may modify or
replace the general terms described in this section.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
This summary and any description of units in the applicable
prospectus supplement, information incorporated by reference or
free writing prospectus is subject to and is qualified in its
entirety by reference to the unit agreement, collateral
arrangements and depositary arrangements, if applicable. We will
file each of these documents, as applicable, with the SEC and
incorporate them by reference as an exhibit to the registration
statement of which this prospectus is a part on or before the time
we issue a series of units. See &#8220;Where You Can Find
Additional Information&#8221; and &#8220;Incorporation of
Information by Reference&#8221; above for information on how to
obtain a copy of a document when it is filed.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The applicable prospectus supplement, information incorporated by
reference or free writing prospectus may describe:</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
the designation and terms of the units and of the securities
comprising the units, including whether and under what
circumstances those securities may be held or transferred
separately;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
any provisions for the issuance, payment, settlement, transfer or
exchange of the units or of the securities composing the units;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
whether the units will be issued in fully registered or global
form; and</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
any other terms of the units.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The applicable provisions described in this section, as well as
those described under &#8220;Description of Common Stock&#8221; and
&#8220;Description of Warrants&#8221; above, will apply to each
unit and to each security included in each unit, respectively.</P>
<P CLASS="LRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: LRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
11</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp11"></A>
USE OF PROCEEDS</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Unless otherwise indicated in the applicable prospectus supplement,
information incorporated by reference or free writing prospectus,
we intend to use the net proceeds from the sale of securities to
fund our growth plans, for working capital, and for other general
corporate purposes, including capital expenditures related to our
growth. More specifically, without limiting the foregoing in any
way, we anticipate that a primary use of the net proceeds would be
to fund a significant portion of the cost of building and equipping
a pharmaceutical plant to produce our Drug Substance (which is the
Active Pharmaceutical Ingredient, Nisin) for Mast Out<FONT CLASS=
"superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>.
This would help us fulfill the manufacturing objectives required to
complete the New Animal Drug Application for Mast Out<FONT CLASS=
"superscript" STYLE=
"font-size: 6pt; mso-style-name: superscript; vertical-align: super;">&#174;</FONT>
with the FDA and build inventory for commercial launch.</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp12"></A>
PLAN OF DISTRIBUTION</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We may sell the securities offered by this prospectus from time to
time in one or more transactions, including, without
limitation:</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
through agents;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
to or through underwriters;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
through broker-dealers (acting as agent or principal);</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
directly by us to purchasers (including our affiliates and
shareholders), through a specific bidding or auction process, a
rights offering or otherwise;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
through a combination of any such methods of sale; or</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
through any other methods described in a prospectus supplement.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The distribution of securities may be effected, from time to time,
in one or more transactions, including:</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
block transactions (which may involve crosses) and transactions on
the NASDAQ Capital Market or any other organized market where the
securities may be traded;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
purchases by a broker-dealer as principal and resale by the
broker-dealer for its own account pursuant to a prospectus
supplement;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
ordinary brokerage transactions and transactions in which a
broker-dealer solicits purchasers;</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
sales &#8220;at the market&#8221; to or through a market maker or
into an existing trading market, on an exchange or otherwise;
and</P>
<P CLASS="BLm" STYLE=
"mso-style-name: BL_m; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 48.0pt; text-indent: -24.0pt; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;">&#8226;</FONT><FONT CLASS="bullet" STYLE=
"mso-style-name: bullet;"><FONT STYLE=
"font-size: 8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>
sales in other ways not involving market makers or established
trading markets, including direct sales to purchasers.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The securities may be sold at a fixed price or prices, which may be
changed, or at market prices prevailing at the time of sale, at
prices relating to the prevailing market prices or at negotiated
prices. The consideration may be cash or another form negotiated by
the parties. Agents, underwriters or broker-dealers may be paid
compensation for offering and selling the securities. That
compensation may be in the form of discounts, concessions or
commissions to be received from us or from the purchasers of the
securities. Dealers and agents participating in the distribution of
the securities may be deemed to be underwriters, and compensation
received by them on resale of the securities may be deemed to be
underwriting discounts and commissions under the Securities Act. If
such dealers or agents were deemed to be underwriters, they may be
subject to statutory liabilities under the Securities Act.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We may also make direct sales through subscription rights
distributed to our existing shareholders on a pro rata basis, which
may or may not be transferable. In any distribution of subscription
rights to our shareholders, if all of the underlying securities are
not subscribed for, we may then sell the unsubscribed securities
directly to third parties or may engage the services of one or more
underwriters, dealers or agents, including standby underwriters, to
sell the unsubscribed securities to third parties.</P>
<P CLASS="RRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: RRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
12</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Some of the securities that we offer through this prospectus may be
new issues of securities with no established trading market. Any
underwriters to whom we sell our securities for public offering and
sale may make a market in those securities, but they will not be
obligated to do so and they may discontinue any market making at
any time without notice. Accordingly, we cannot assure you of the
liquidity of, or continued trading markets for, any securities that
we offer.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Agents may, from time to time, solicit offers to purchase the
securities. If required, we will name in the applicable prospectus
supplement, document incorporated by reference or free writing
prospectus, as applicable, any agent involved in the offer or sale
of the securities and set forth any compensation payable to the
agent. Unless otherwise indicated, any agent will be acting on a
best efforts basis for the period of its appointment. Any agent
selling the securities covered by this prospectus may be deemed to
be an underwriter of the securities.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
If underwriters are used in an offering, securities will be
acquired by the underwriters for their own account and may be
resold, from time to time, in one or more transactions, including
negotiated transactions, at a fixed public offering price or at
varying prices determined at the time of sale, or under delayed
delivery contracts or other contractual commitments. Securities may
be offered to the public either through underwriting syndicates
represented by one or more managing underwriters or directly by one
or more firms acting as underwriters. If an underwriter or
underwriters are used in the sale of securities, an underwriting
agreement will be executed with the underwriter or underwriters at
the time an agreement for the sale is reached. The applicable
prospectus supplement will set forth the managing underwriter or
underwriters, as well as any other underwriter or underwriters,
with respect to a particular underwritten offering of securities,
and will set forth the terms of the transactions, including
compensation of the underwriters and dealers and the public
offering price, if applicable. This prospectus, the applicable
prospectus supplement and any applicable free writing prospectus
will be used by the underwriters to resell the securities.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
If a dealer is used in the sale of the securities, we, or an
underwriter, will sell the securities to the dealer, as principal.
The dealer may then resell the securities to the public at varying
prices to be determined by the dealer at the time of resale. To the
extent required, we will set forth in the prospectus supplement
document incorporated by reference or free writing prospectus, as
applicable, the name of the dealer and the terms of the
transactions.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
We may directly solicit offers to purchase the securities and may
make sales of securities directly to institutional investors or
others. These persons may be deemed to be underwriters with respect
to any resale of the securities. To the extent required, the
prospectus supplement, document incorporated by reference or free
writing prospectus, as applicable, will describe the terms of any
such sales, including the terms of any bidding or auction process,
if used.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Agents, underwriters and dealers may be entitled under agreements
which may be entered into with us to indemnification by us against
specified liabilities, including liabilities incurred under the
Securities Act, or to contribution by us to payments they may be
required to make in respect of such liabilities. If required, the
prospectus supplement, documents incorporated by reference or free
writing prospectus, as applicable, will describe the terms and
conditions of such indemnification or contribution. Some of the
agents, underwriters or dealers, or their affiliates may be
customers of, engage in transactions with or perform services for
us or our subsidiaries or affiliates in the ordinary course of
business.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Under the securities laws of some states, the securities offered by
this prospectus may be sold in those states only through registered
or licensed brokers or dealers.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Any person participating in the distribution of common stock
registered under the registration statement that includes this
prospectus will be subject to applicable provisions of the Exchange
Act, and the applicable SEC rules and regulations, including, among
others, Regulation M, which may limit the timing of purchases and
sales of any of our common stock by any such person. Furthermore,
Regulation M may restrict the ability of any person engaged in the
distribution of our common stock to engage in market-making
activities with respect to our common stock. These restrictions may
affect the marketability of our common stock and the ability of any
person or entity to engage in market-making activities with respect
to our common stock.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
Certain persons participating in an offering may engage in
over-allotment, stabilizing transactions, short-covering
transactions and penalty bids in accordance with Regulation M under
the Exchange Act that stabilize, maintain or otherwise affect the
price of the offered securities. If any such activities will occur,
they will be described in the applicable prospectus supplement.</P>
<P CLASS="LRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: LRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
13</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
In compliance with the guidelines of the Financial Industry
Regulatory Authority (&#8220;FINRA&#8221;), the aggregate maximum
discount, commission or agency fees or other items constituting
underwriting compensation to be received by any FINRA member or
independent broker-dealer will not exceed 8% of any offering
pursuant to this prospectus and any applicable prospectus
supplement, as the case may be.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
If more than 10% of the net proceeds of any offering of securities
made under this prospectus will be received by FINRA members
participating in the offering or affiliates or associated persons
of such FINRA members, the offering will be conducted in accordance
with FINRA Conduct Rule 5110(h).</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
So long as the aggregate market value of our common equity held by
non-affiliates is less than $75,000,000.00 and so long as required
by the rules of the SEC, the amount of securities we may offer
hereunder will be limited such that the aggregate market value of
securities sold by us during a period of 12 calendar months cannot
exceed one-third of the aggregate market value of the common equity
held by non-affiliates.</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
To the extent required, this prospectus may be amended or
supplemented from time to time to describe a specific plan of
distribution.</P>
<P CLASS="RRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: RRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
14</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp13"></A>
LEGAL MATTERS</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
<FONT STYLE="letter-spacing: -.05pt;">Pierce Atwood LLP will pass
upon legal matters in connection with the validity of the
securities offered hereby for us.</FONT></P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp14"></A>
EXPERTS</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
The financial statements incorporated in this Prospectus by
reference to the Annual Report on Form 10-K for the year ended
December 31, 2014 have been audited by Baker Newman &amp; Noyes
LLC, an independent registered public accounting firm, as stated in
their reports incorporated by reference herein, and have been so
incorporated in reliance upon such reports and upon the authority
of such firm as experts in accounting and auditing.</P>
<P CLASS="H1" STYLE=
"mso-style-name: H1; margin-top: 12.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; text-align: center; line-height: 12.0pt; page-break-after: avoid; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Bold; color: black; font-weight: bold;"><A NAME="bp15"></A>
INTERESTS OF NAMED EXPERTS AND COUNSEL</P>
<P CLASS="Textflush" STYLE=
"mso-style-name: Text_flush; margin-top: 8.0pt; margin-right: 0in; margin-bottom: .0001pt; margin-left: 0in; line-height: 12.0pt; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
No expert or counsel named in this prospectus as having prepared or
certified any part of this prospectus or having given an opinion
upon the validity of the securities being registered or upon other
legal matters in connection with the registration or offering of
the securities was employed on a contingency basis, or had, or is
to receive, in connection with the offering, a substantial
interest, direct or indirect, in the registrant. Nor was any such
person connected with the registrant as a promoter, managing or
principal underwriter, voting trustee, director, officer, or
employee.</P>
<P CLASS="LRH" STYLE=
"margin: 10px 0px 10px 0px; page-break-after: always; border-bottom: 1px solid; mso-style-name: LRH; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; text-autospace: none; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">
15</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P /X# 2(  A$! Q$!_\0
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M-'@/PAI?C&]\<W6N2MI7B'6D%K_PD"SZ&2(D\-2"6600!-WE!'#-\YKG?^"
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M#_@CA^U!\"OAY^SKXX^'WQ(^)OA7P#XGTCX@ZOXB-CXH\0>'](6\TCQ#X?\
M#4D<V@ RQ&2-)$4%$WL7*$)M5F4.>Z[K[U_F?G9_P6'_ .3]/'?_ &+_ ,,O
M_4?\,U^F7_!=B^N&_9^^ =AYVVWO/B +N_;NR1^'LH?H&D?:.O/Y?C!_P4(^
M-_A/]H3]K[XB?$?P#<K=^#[R]\&>']#UM<[=2;PWX>'AIO$"AAG:#]T'D*!Q
MQ7]+_P#P4V_9NU;]HS]D.^TOP?;)+XY^'#Z/\0O"E@T@7^T7T/2G&NZ$%.!N
MO/#LEP$Y.]D1%!9AD-[KW=5]Z[>IY+_P0\M]-B_8^URY@_X^;OXN^+VO_JNA
M^%R.![!L]<<#UK]FJ_D-_P""6'[?WA/]DV^\:_"[XS+JNE_#3QAK4NO:;KEC
M:R7Q\%^,G7/B.+Q'HT*M/;H\BQL\D2LZ[ P20J%K]//VQ_\ @K%^SQX;^#?B
M_P -_ /QJOQ$^*'BO0M2T/P\="L-<.C^&W\01/%_;OB'7#$%@CC9O,B,;ERS
M'<450KAA==U]Z_S/VVK^*;]M_P"*=Q^U-^WYKWAKQ]XU'A+X<>&_B8WP@L-<
MOL#2/!/@[P[XB/ASQ+XBX[EB?&9/4L23R37Z"?\ !%G7_P!J/XA^,/&6M^)O
MB=\0]9^ /A/1%TF/0_%-_-JVCW_C*5A&^B^'I/$*F2*.%&:1WW1@*NSS8V<,
M/S'_ &GOAYH7PA_X* ?$7P[\;M%U:[^'%Y\:3XOU\6)']L:A\-O$7B$^(VUW
MP]AB Z>%@R2+DX=&4\K0%UW7WK_,^U?VN/V;O^"9^A_ #7]9_9T^-'@\_%[P
MC8:=J6G6L?CP^*O^%@K&\2ZY%+X;:60S2SH\DK2QK''$8C$5)9';[)_X(<?'
M3Q-XX^%'Q+^"_B34KO5+?X0:GH=]X7-XJ^99:#XE2:-?#I9@?D@DT0W(!SC_
M (2-PJDN0?G?XZ?!_P#X(\?![X3VWQ/\-7UW\5M3U9=%/A+P7X&^+JGQ9JC$
MC"Q@?/X8"C<)&E6$[@-B.&)3[@_X)/6_[+NNZ)\5?'?[-OPK^*GPSMKV?2/"
MOBBZ^(>M'5-+U35H1N4>'0TKD^6Y0R2J%5MT:;(RXW 77=?>O\S\6/V*/^4K
M7@__ ++1\3?_ %'O$U?6G_!?/_DJ/P#_ .R?^,/_ $^BODO]BC_E*UX/_P"R
MT?$W_P!1[Q-7UI_P7T_Y*E\ _P#LG_C#_P!/HH-[J^ZV[KOZG[I_L'_\F;_L
MT?\ 9(O!G_IEAKZWKY'_ &#SC]C?]FC)'_)(O!GY?V+#C_/K7UOD>H_,46?9
M_<S"Z[K[U_F+129'J/S%&1ZC\Q3L^S^Y_P"077=?>O\ ,6BDR/4?F*,CU'YB
MBS[/[G_D%UW7WK_,6BDR/4?F*,CU'YBBS[/[G_D%UW7WK_,6BDR/4?G2TKI;
MM+U:7YL9^;'[3_\ P3.^ 7[6OQ$L_B7\3_$WQ3TS7K3PK9^$5LO!/B+1=%TH
MZ0LSOLVS^&;R:5F=F+R>< J@,L:*5B'L7Q8_8^^%?QD_9]TC]FSQ5KGC.V\!
M>'[#PE96%[H6I:1I/BM(O"85/#^-<;0)8A)#L D>"VBW,3N57=B?ASQ3_P $
MROVDO$?B;7=?T_\ X*9?M):!8ZKK>HZE9>'].D(TC2XY6"#1(U;Q*&,*.'R1
M@KL;*Y %8Q_X)6?M.C'_ !M+_:G.?29N/_+@_P ^M>%_:><W_P"1.O\ P93?
M?ND?K&'X%\/FD_\ B,?":>C_ .21XP;V3L^7(VV];.^S5C[X_92_8_\ AG^Q
MWX1\1^"OA3K7C#4-*\6Z_P#\)#J3^.=:TO6]5;5CI:1';<0:#8JH*H2Z2+*%
M)#_.J%9/!?CE_P $M_V<_P!H3XXZU\=O'?BGXI6WCG6;KPCJ6H6WA7Q5HNBZ
M,W_"+:!;^&_#^+=_#$\IV1:,FXM<LSRAL[5;CP+_ (=7?M/_ /24G]IS_OX?
M_FCH_P"'5?[3O_24S]J;_O\ -_\ -!2>9YS_ -">/_@RG_D='^H_A_K_ ,;D
MX2U5G_QB'&5OE_PA:?+4_5_XM_"?P[\9OA?XN^$?BJ^U"T\,>,="?P]J<^B7
MG]FZJ--D5 5BND4M&1MVME6# G*@\CYF_9(_8&^#/[&&I^,M<^$NN>/=2OO'
M=CH]AKR^.-9T+5V*:"&6!HFT/PQIH24@X?\ UG)*KAFX^.?^'5?[3O\ TE,_
M:F_[_-_\T%'_  ZN_:?_ .DI/[3G_?P__-'3_M3.O^A0O_!E/_(G_4;P_2:_
MXC)PEKWX1XSOKO9_V(Y+RLU;7OI[]!_P2Q_9RMOVBKC]I^'Q-\4A\1KOXF?\
M+?>S_P"$NT8>$?\ A+O[=/B':N@_\(D8QH'VOY/L_GN_EG/F%^3]7?M+?LX^
M!?VJ/A3J7PD^(NK>(=.\,7^HZ7J<MSX6U-M&U83:+,98MLZ12_(2TBL&B+'*
M,O"[7_-/_AU7^T[_ -)3/VIO^_S?_-!1_P .J_VG?^DIG[4W_?YO_F@I?VIG
M/_0HC_X,I?Y#? WA_=/_ (C)PEI_U2'&5OFED:3^::\C[W_92_8_^&?['?A'
MQ'X*^%.M>,-0TKQ;K_\ PD.I/XYUK2];U5M6.EI$=MQ!H-BJ@JA+I(LH4D/\
MZH5D\$^./_!+K]G?]H/XXZE\>/'?BGXIVOC;5KOPEJ6H67A;Q9H^C^%V/A;P
M_!X=\/@6S>%9Y7\N+1H/,<W#NTK@[0'!KP/_ (=5_M._])3/VIO^_P W_P T
M%'_#J[]I_P#Z2D_M.?\ ?P__ #1T?VGG/_0GC_X,I_Y#_P!1_#__ */)PEK_
M -4AQE;Y+^PM#];?B=\+_!7QB\ Z[\,_B-IECXB\&^); Z?K6F7@4I-$0I&6
MZAPW*MGC."&4D'\<_P#AP_\ LW_V]]L_X6A\4O\ A'/M6[^P/M&A_P!I?V=C
M_4?\))Y'VC;GCS?LN[9\WD[ODK?_ .'5W[3_ /TE)_:<_P"_A_\ FCH_X=5_
MM._])3/VIO\ O\W_ ,T%/^T\YZY0O_!E+_(2X&\/U?\ XW)PB[ZN_"'&<ONY
MLD=NNBLK6T5M?1_B'_P1X_8[\?W?A:[A@\=^ K+PCH.GZ%8:+X"U_0]*TS4D
MB91#X@UZWU_PIJ!G\3L"1+,)HRA53Y&7"+^L4,4<44,*SQ8A55'R@G   Y)S
MWY^A/89_%3_AU3^TU_TE*_:D_P"_A_\ E_1_PZM_:=_Z2D?M.?\ ?3?_ #14
M_P"T\X_Z$[_\&4O\@? ?ALTDO&;A!-;VX0XS5_5K)4WUW\NQ[[^TG_P2G_9;
M_:/U[4?&5QIVJ_#KQSJKB^U/7_ &H?V'I_B'4\';+XCT)5>"];(&=GD$*<L7
ME4A_F_PU_P $)_V<-'U>SU'Q)\3OB5XNT^T&3H;/HFD0WQ Z/+%%, ?3Y<>I
M'%:O_#J[]I__ *2D_M.?]_#_ /-'1_PZN_:?_P"DI/[3G_?P_P#S1TO[3SG_
M *$Z_P# Z?\ D"X'\/DK?\1DX1MKOP?QBW;U>1_G?]3]:_AG\+OA]\&/!NF^
M _ACX;T?PEX/T9"NGZ)HT6R"+)7<5W,2S,0,DN1\I V@8KYX_:K_ &'O@)^U
M]I^F6OQ0TF>V\1:($_L+QMX8OVTCQ9ID(9R^DBY2%A+H,Q<--;.1O90R-&2\
MDGPS_P .J?VFO^DI7[4G_?P__+^C_AU;^T[_ -)2/VG/^^F_^:*G_:><?]"=
M_P#@RE_D)<!^&M[_ /$9N$';6W^J/&EK]+IY+:U][+7LNG.:-_P0=_9WL;^W
MN=;^+7Q+UFPQ_ING6C:)HR:DWH\L<4P0=\A'Y[8YK]D/A7\*/ 7P2\"Z'\./
MAEH>G>%?!OARS^R:7HEC$!%%$H'5V8EG;#%FW 9/RA5&*_)3_AU=^T__ -)2
M?VG/^_A_^:.C_AU=^T__ -)2?VG/^_A_^:.E_:>=?]"=?^#*?^0Y<#>'TK7\
M9.$4E?;A#C..FWV<D3V[NQ[S\-?^"67[-WPJ^/>G_M%>&?$_Q4N/'FF>*M<\
M5QV.L>+='E\)?VUXB%T)BWA^'PK!L^769!&T<Z2(X!+JVT5Z)^UC_P $_/@G
M^V;K7A#7OBQXA\>Z=>>#M/U31]+'@G7='T0B*[D9V\V2?PY?2O(KF5R2R@#;
M&JA5W5\@?\.K?VG?^DI'[3G_ 'TW_P T5'_#JW]IW_I*1^TY_P!]-_\ -%3_
M +3SC_H3_P#E2E_D/_43PV_Z/+PA?SX0XRM\U_8BZ['ZS_"CX:^'_A!\-_!7
MPN\+WU_<>'/ GA_2/#FBW&M7IU/4Y-,T2*.&#SYV"F1@BI'N !";5Q\BY],W
M)_SVB_[Y'M[^_P"A]*_$S_AU;^T[_P!)2/VG/^^F_P#FBH_X=6_M._\ 24C]
MIS_OIO\ YHJ?]J9Q_P!"=_\ @VE_D2^ O#9[>,_"*].$>-5^63+_ "71'[9[
MD_Y[1?\ ?(]O?W_0^E&Y/^>T7_?(]O?W_0^E?B9_PZM_:=_Z2D?M.?\ ?3?_
M #14?\.K?VG?^DI'[3G_ 'TW_P T5']J9Q_T)Y?^#:?^0O\ 4+PW_P"CT<)?
M^(EQK_\ .<_;/<G_ #VB_P"^1[>_O^A]*-R?\]HO^^1[>_O^A]*_$S_AU1^T
MU_TE)_:D_P"_A_\ E_1_PZH_::_Z2D_M2?\ ?P__ "_H_M3./^A/+_P;3_R%
M_J%X;?\ 1Z.$O_$2XU_^<Q^V>Y/^>T7_ 'R/;W]_T/I2AD!!\Z+@@_='M[^_
MZ'TK\2_^'5O[3O\ TE(_:<_[Z;_YHJ/^'5O[3G?_ (*D?M.?FW_S14/-,XL_
M^$>77_E[3_R'_J%X;_\ 1Z.$OEPEQK?Y?\(ZU[;:V/VP,\<:L7=(\G&PE58C
M).07.1VY!P3W')IZS1NBMP%).UBQ<G'J8PWUP0,=.U?B0_\ P2C_ &D209/^
M"H_[4)]V56/Z^(3Z^HZFON?]E#]FOQU^S?X9\2Z)X^_:3^(O[0MUK^NOJMEK
M?Q+ELX[GP];LA5=%TG;(P^Q+RXSAB5S@8YZ<+B<5BU;&934IN[?,Y0E%66B]
MWWM7:S;;U[:G@Y[PKP=E65/%Y/XCX3B3,N:$?J>'X7XHP]1QE-*353&0A1M&
*/O625U&V[2/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
